Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1

New England Journal of Medicine

Volumn 373, Issue 8, 2015, Pages 714-725

  Wyles, D L ^a   Ruane, P J ^b   Sulkowski, M S ^h   Dieterich, D ⁱ   Luetkemeyer, A ^e   Morgan, T R ^f   Sherman, K E ^j   Dretler, R ^k   Fishbein, D ^l   Gathe, J C ^o   Henn, S ^m   Hinestrosa, F ^q   Huynh, C ^c   McDonald, C ^p   Mills, A ^d   Overton, E T ^s   Ramgopal, M ^r   Rashbaum, B ⁿ   Ray, G ^t   Scarsella, A ^g   Yozviak, J ^u   McPhee, F ^v   Liu, Z ^w   Hughes, E ^w   Yin, P D ^v   Noviello, S ^w   Ackerman, P ^v   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Ruane Medical and Liver Health Institute   (United States)

^c LOS ANGELES LGBT CENTER   (United States)

^d Southern California s Men s Medical Group Men s Health Foundation   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Long Beach VA Healthcare System   (United States)

^g Pacific Oaks Medical Group   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^k Infectious Disease Specialists of Atlanta   (United States)

^l WASHINGTON HOSPITAL CENTER   (United States)

^m WhitmanWalker GMHW Clinic   (United States)

ⁿ Capital Medical   (United States)

^o Cure C Consortium   (United States)

^p Tarrant County Infectious Disease Associates   (United States)

^q ORLANDO IMMUNOLOGY CENTER   (United States)

^r Midway Immunology and Research Center   (United States)

^s UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^t UNIVERSITY OF COLORADO   (United States)

^u LEHIGH VALLEY HOSPITAL   (United States)

^v BRISTOL MYERS SQUIBB   (United States)

^w NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; DACLATASVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; RALTEGRAVIR; RILPIVIRINE; SOFOSBUVIR; TRIACYLGLYCEROL LIPASE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; URIDINE PHOSPHATE; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; VIRUS GENE; VOMITING; ANALOGS AND DERIVATIVES; ANTIVIRAL RESISTANCE; BLOOD; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; VIRUS LOAD;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; RNA, VIRAL; URIDINE MONOPHOSPHATE; VIRAL LOAD;

EID: 84939833091     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1503153     Document Type: Article

References (38)

1. Smith CJ, Ryom L, Weber R, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D: A: D): A multicohort collaboration. Lancet 2014; 384: 241-8.
2. Reiberger T, Ferlitsch A, Sieghart W, et al. HIV-HCV co-infected patients with low CD4+ cell nadirs are at risk for faster fibrosis progression and portal hypertension. J Viral Hepat 2010; 17: 400-9.
3. Macías J, Berenguer J, Japón MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/ hepatitis C virus. Hepatology 2009; 50: 1056-63.
4. Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: A meta-analysis. AIDS 2008; 22: 1979-91.
5. Weber R, Sabin CA, Friis-Miller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D: A: D study. Arch Intern Med 2006; 166: 1632-41.
6. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: Suppl: S6-S9.
7. Qurishi N, Kreuzberg C, Lüchters G, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362: 1708-13.
8. Lo Re V III, Kallan MJ, Tate JP, et al. Hepatic decompensation in antiretroviral- treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study. Ann Intern Med 2014; 160: 369-79.
9. Reiberger T, Obermeier M, Payer BA, et al. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011; 16: 815-24.
10. Grint D, Peters L, Schwarze-Zander C, et al. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. HIV Med 2013; 14: 614-23.
11. Gatti F, Nasta P, Matti A, et al. Treating hepatitis C virus in HIV patients: Are side effects a real obstacle? AIDS Rev 2007; 9: 16-24.
12. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.
13. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
14. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: A randomized controlled trial. JAMA 2004; 292: 2839-48.
15. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, doubleblind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
16. Sulkowski MS, Sherman KE, Dieterich DT, et al. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: A randomized trial. Ann Intern Med 2013; 159: 86-96.
17. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: Implications for HIV and transplant patients. Ann Hepatol 2012; 11: 179-85.
18. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. (http: //aidsinfo .nih .gov/ guidelines).
19. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93.
20. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889-98.
21. Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-92.
22. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet 2014; 384: 1756-65.
23. Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK- 5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, open-label phase 2 trial. Lancet 2015; 385: 1075-86. [Erratum, Lancet 2015; 385: 1074.]
24. Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study. Lancet 2014; 384: 1597-605.
25. Everson GT, Sims KD, Rodriguez-Torres M, et al. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatmentnaive patients with HCV genotype 1 infection. Gastroenterology 2014; 146: 420-9.
26. Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010; 465: 96-100.
27. Sofia MJ, Bao D, Chang W, et al. Discovery of a ß-d-2'-deoxy-2'-a-fluoro-2'-ß- C-methyluridine nucleotide prodrug (PSI- 7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53: 7202-18.
28. Sulkowski MS, Gardiner DF, Rodriguez- Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21.
29. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-88.
30. Sovaldi (sofosbuvir) U.S. prescribing information. Foster City, CA: Gilead Sciences, December 2013 (http: //www .accessdata .fda .gov/ drugsatfda-docs/ label/ 2013/ 204671s000lbl .pdf).
31. Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: Ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013; 18: 931-40.
32. Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus- infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis 2014; 59: 1666-74.
33. Harvoni (ledipasvir and sofosbuvir) U.S. prescribing information. Foster City, CA: Gilead Sciences, October 2014 (http: // www .accessdata .fda .gov/ drugsatfda-docs/ label/ 2014/ 205834s000lbl .pdf).
34. Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (CWORTHY): A randomised, open-label phase 2 trial. Lancet 2015; 385: 1087-97.
35. Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA 2015; 313: 1232-9.
36. Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: A randomized trial. JAMA 2015; 313: 1223-31.
37. Eley T, You X, Wang R, et al. Daclatasvir: Overview of drug-drug interactions with antiretroviral agents and other common concomitant drugs. Global Antiviral Journal 2014; 10: Suppl 1: 54-5.
38. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35.